Xeris Biopharma (XERS) Projected to Post Earnings on Monday

Xeris Biopharma (NASDAQ:XERS) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of $0.03 per share and revenue of $86.00 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 2, 2026 at 8:30 AM ET.

Xeris Biopharma Trading Down 9.2%

Shares of NASDAQ XERS opened at $6.12 on Friday. The business has a 50-day moving average of $7.23 and a 200-day moving average of $7.64. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -61.19 and a beta of 0.52. Xeris Biopharma has a 12 month low of $3.59 and a 12 month high of $10.08.

Insider Transactions at Xeris Biopharma

In other news, insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $7.43, for a total transaction of $123,835.81. Following the completion of the transaction, the insider directly owned 1,308,103 shares of the company’s stock, valued at approximately $9,719,205.29. This represents a 1.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the business’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $7.09, for a total value of $106,350.00. Following the transaction, the director owned 142,500 shares in the company, valued at approximately $1,010,325. This represents a 9.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 240,308 shares of company stock valued at $1,745,120. Company insiders own 6.47% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Cetera Investment Advisers lifted its stake in shares of Xeris Biopharma by 3.9% in the second quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock worth $216,000 after buying an additional 1,735 shares in the last quarter. Royal Bank of Canada lifted its position in Xeris Biopharma by 6.5% in the 4th quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock valued at $304,000 after acquiring an additional 2,351 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in Xeris Biopharma during the 4th quarter valued at $25,000. The Manufacturers Life Insurance Company boosted its stake in Xeris Biopharma by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 54,472 shares of the company’s stock valued at $254,000 after purchasing an additional 3,562 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Xeris Biopharma by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after purchasing an additional 3,594 shares in the last quarter. Institutional investors own 42.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on XERS. Oppenheimer reissued an “outperform” rating and issued a $18.00 price target on shares of Xeris Biopharma in a report on Friday, November 7th. Piper Sandler increased their target price on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, January 21st. Barclays started coverage on Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 price objective on the stock. Finally, Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.08.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.